ASSESSMENT OF SUPPORTING EVIDENCE AND POSTMARKETING REQUIREMENTS FOR THERAPEUTIC INDICATIONS WITH REAL-TIME ONCOLOGY DRUG REVIEW, 2018-2023

被引：0
|
作者：
Mooghali, M. [1 ]
Mohammad, A. [2 ]
Wallach, J. D. [3 ]
Mitchell, A. P. [4 ]
Ross, J. S. [1 ]
Ramachandran, R. [1 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Icahn Sch Med Mt Sinai, New York, NY USA
[3] Emory Univ, Atlanta, GA USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR82
引用
收藏
页码：S208 / S208
页数：1
相关论文
共 3 条
  • [1] Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals
    Mooghali, Maryam
    Mohammad, Ayman
    Wallach, Joshua D.
    Mitchell, Aaron P.
    Ross, Joseph S.
    Ramachandran, Reshma
    JAMA NETWORK OPEN, 2024, 7 (05) : E249233
  • [2] US Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program
    de Claro, R. Angelo
    Gao, Jennifer J.
    Kim, Tamy
    Kluetz, Paul G.
    Theoret, Marc R.
    Beaver, Julia A.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 11 - 14
  • [3] Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid
    Marquerita Algorri
    Ajay Acharya
    James Bernstein
    Nina S. Cauchon
    Xiao Hong Chen
    Kim Huynh-Ba
    Carol Krantz
    Tao Li
    Yiwei Li
    Sherita McLamore
    Scott W. Roberts
    David Schwinke
    Rakhi Shah
    Andrea Schirmer
    Helen Strickland
    Kin Tang
    Timothy Watson
    AAPS Open, 8 (1)
1